Gold prices slip as stronger dollar, Fed rate uncertainty weigh
Kenvue Inc’s stock reached a new 52-week low, hitting 14.04 USD recently. This marks a significant downturn for the company, reflecting a 38.29% decline in its stock price over the past year. The fall to this new low underscores the challenges Kenvue has faced in the market, as investors continue to react to various factors influencing the company’s performance. The 52-week low serves as a critical point of reflection for stakeholders assessing Kenvue’s future prospects amidst a volatile economic landscape.
In other recent news, Kenvue Inc. announced a quarterly dividend of $0.2075 per share, payable on November 26, 2025, to shareholders of record as of November 12, 2025. Meanwhile, Jefferies has lowered its price target for Kenvue to $23, citing slowing retail trends and ongoing litigation concerns, although it maintained a Buy rating on the stock. Evercore ISI reiterated an In Line rating with a price target of $18, as Kenvue faces headwinds with U.S. retail sales contracting significantly as it enters the fourth quarter. Additionally, Kenvue is dealing with a UK class action lawsuit involving allegations that Johnson & Johnson’s talcum products, for which Kenvue is a codefendant, cause cancer. This lawsuit involves 2,000 plaintiffs linking their diagnoses to baby powder usage over several decades. U.S. Health Secretary Robert F. Kennedy Jr. also commented on the inconclusive evidence linking Kenvue’s Tylenol to autism, advising caution in its use. These developments highlight the various challenges and considerations currently facing Kenvue and its investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.